Alnylam presents positive results from the kardia-2 phase 2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced positive results from the kardia-2 phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan). zilebesiran is an investigational rnai t.
ALNY Ratings Summary
ALNY Quant Ranking